Literature DB >> 22474264

Triggers of hospitalization for venous thromboembolism.

Mary A M Rogers1, Deborah A Levine, Neil Blumberg, Scott A Flanders, Vineet Chopra, Kenneth M Langa.   

Abstract

BACKGROUND: The rate of hospitalization for venous thromboembolism (VTE) is increasing in the United States. Although predictors of hospital-acquired VTE are well-known, triggers of VTE before hospitalization are not as clearly defined. The objective of this study was to evaluate triggers of hospitalization for VTE. METHODS AND
RESULTS: A case-crossover study was conducted. Subjects were participants in the Health and Retirement Study, a nationally representative sample of older Americans. Data were linked to Medicare files for hospital and nursing home stays, emergency department visits, outpatient visits including physician visits, and home health visits from years 1991 to 2007 (n=16 781). The outcome was hospitalization for venous thromboembolism (n=399). Exposures during the 90-day period before hospitalization for VTE were compared with exposures occurring in 4 comparison periods. Infection was the most common trigger of hospitalization for VTE, occurring in 52.4% of the risk periods before hospitalization. The adjusted incidence rate ratios (IRRs; 95% confidence interval) were 2.90 (2.13, 3.94) for all infection, 2.63 (1.90, 3.63) for infection without a previous hospital or skilled nursing facility stay, and 6.92 (4.46, 10.72) for infection with a previous hospital or skilled nursing facility stay. Erythropoiesis-stimulating agents and blood transfusion were also associated with VTE hospitalization (IRR=9.33, 95% confidence interval: 1.19, 73.42; IRR=2.57, 95% confidence interval: 1.17, 5.64; respectively). Other predictors included major surgeries, fractures (IRR=2.81), immobility (IRR=4.23), and chemotherapy (IRR=5.70). These predictors, combined, accounted for a large proportion (69.7%) of exposures before VTE hospitalization as opposed to 35.3% in the comparison periods.
CONCLUSIONS: Risk prediction algorithms for VTE should be reevaluated to include infection, erythropoiesis-stimulating agents, and blood transfusion.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22474264      PMCID: PMC3342773          DOI: 10.1161/CIRCULATIONAHA.111.084467

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  30 in total

1.  Tutorial in biostatistics: the self-controlled case series method.

Authors:  Heather J Whitaker; C Paddy Farrington; Bart Spiessens; Patrick Musonda
Journal:  Stat Med       Date:  2006-05-30       Impact factor: 2.373

Review 2.  The impact of the inflammatory response on coagulation.

Authors:  Charles T Esmon
Journal:  Thromb Res       Date:  2004       Impact factor: 3.944

3.  The case-crossover design: a method for studying transient effects on the risk of acute events.

Authors:  M Maclure
Journal:  Am J Epidemiol       Date:  1991-01-15       Impact factor: 4.897

4.  Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer.

Authors:  P S Wells; D R Anderson; M Rodger; J S Ginsberg; C Kearon; M Gent; A G Turpie; J Bormanis; J Weitz; M Chamberlain; D Bowie; D Barnes; J Hirsh
Journal:  Thromb Haemost       Date:  2000-03       Impact factor: 5.249

Review 5.  New links between inflammation and thrombosis.

Authors:  Denisa D Wagner
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-04-14       Impact factor: 8.311

Review 6.  Should we use a case-crossover design?

Authors:  M Maclure; M A Mittleman
Journal:  Annu Rev Public Health       Date:  2000       Impact factor: 21.981

7.  Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography.

Authors:  Arne van Belle; Harry R Büller; Menno V Huisman; Peter M Huisman; Karin Kaasjager; Pieter W Kamphuisen; Mark H H Kramer; Marieke J H A Kruip; Johanna M Kwakkel-van Erp; Frank W G Leebeek; Mathilde Nijkeuter; Martin H Prins; Maaike Sohne; Lidwine W Tick
Journal:  JAMA       Date:  2006-01-11       Impact factor: 56.272

Review 8.  Does this patient have deep vein thrombosis?

Authors:  Philip S Wells; Carolyn Owen; Steve Doucette; Dean Fergusson; Huyen Tran
Journal:  JAMA       Date:  2006-01-11       Impact factor: 56.272

9.  Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study.

Authors:  Raza Alikhan; Alexander T Cohen; Sophie Combe; Meyer M Samama; Louis Desjardins; Amiram Eldor; Charles Janbon; Alain Leizorovicz; Carl-Gustav Olsson; Alexander G G Turpie
Journal:  Arch Intern Med       Date:  2004-05-10

10.  Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting.

Authors:  Liam Smeeth; Claire Cook; Sara Thomas; Andrew J Hall; Richard Hubbard; Patrick Vallance
Journal:  Lancet       Date:  2006-04-01       Impact factor: 79.321

View more
  52 in total

1.  Heart disease and stroke statistics--2014 update: a report from the American Heart Association.

Authors:  Alan S Go; Dariush Mozaffarian; Véronique L Roger; Emelia J Benjamin; Jarett D Berry; Michael J Blaha; Shifan Dai; Earl S Ford; Caroline S Fox; Sheila Franco; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Mark D Huffman; Suzanne E Judd; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Rachel H Mackey; David J Magid; Gregory M Marcus; Ariane Marelli; David B Matchar; Darren K McGuire; Emile R Mohler; Claudia S Moy; Michael E Mussolino; Robert W Neumar; Graham Nichol; Dilip K Pandey; Nina P Paynter; Matthew J Reeves; Paul D Sorlie; Joel Stein; Amytis Towfighi; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner
Journal:  Circulation       Date:  2013-12-18       Impact factor: 29.690

Review 2.  The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs.

Authors:  Scott D Grosse; Richard E Nelson; Kwame A Nyarko; Lisa C Richardson; Gary E Raskob
Journal:  Thromb Res       Date:  2015-11-24       Impact factor: 3.944

3.  Learning to predict post-hospitalization VTE risk from EHR data.

Authors:  Emily Kawaler; Alexander Cobian; Peggy Peissig; Deanna Cross; Steve Yale; Mark Craven
Journal:  AMIA Annu Symp Proc       Date:  2012-11-03

4.  Sickle cell disease in pregnancy: maternal complications in a Medicaid-enrolled population.

Authors:  Sheree L Boulet; Ekwutosi M Okoroh; Ijeoma Azonobi; Althea Grant; W Craig Hooper
Journal:  Matern Child Health J       Date:  2013-02

5.  Venous thromboembolism and subsequent permanent work-related disability.

Authors:  S K Braekkan; S D Grosse; E M Okoroh; J Tsai; S C Cannegieter; I A Naess; S Krokstad; J-B Hansen; F E Skjeldestad
Journal:  J Thromb Haemost       Date:  2016-08-17       Impact factor: 5.824

Review 6.  [Pulmonary embolism].

Authors:  M Hecker; N Sommer; A Hecker; D Bandorski; M A Weigand; G A Krombach; E Mayer; D Walmrath
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-11-30       Impact factor: 0.840

7.  Infection as cause of immobility and occurrence of venous thromboembolism: analysis of 1635 medical cases from the RIETE registry.

Authors:  Stefania Frasson; Gualberto Gussoni; Pierpaolo Di Micco; Raquel Barba; Laurent Bertoletti; Manuel J Nuñez; Beatriz Valero; Angel Luis Samperiz; Agustina Rivas; Manuel Monreal
Journal:  J Thromb Thrombolysis       Date:  2016-04       Impact factor: 2.300

8.  Venous Thromboembolism After Intraventricular Hemorrhage: Results From the CLEAR III Trial.

Authors: 
Journal:  Neurosurgery       Date:  2019-03-01       Impact factor: 4.654

9.  Hospitalization with infection and incident venous thromboembolism: The ARIC study.

Authors:  Logan T Cowan; Pamela L Lutsey; James S Pankow; Mary Cushman; Aaron R Folsom
Journal:  Thromb Res       Date:  2017-01-25       Impact factor: 3.944

10.  Risk of venous thromboembolism in cancer patients treated with epoetins or blood transfusions.

Authors:  Antonios Douros; Kathrin Jobski; Bianca Kollhorst; Tania Schink; Edeltraut Garbe
Journal:  Br J Clin Pharmacol       Date:  2016-06-22       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.